Pomerantz Law Firm Investigates Possible Securities Fraud Against Altimmune Inc.

Investor Alert on Altimmune Inc.

Pomerantz LLP, a leading law firm known for its role in securities class actions, is currently investigating potential claims from investors of Altimmune, Inc. (NASDAQ: ALT). The firm is focused on whether Altimmune's executives and board members engaged in any fraudulent practices or unlawful business conduct that may have negatively impacted investors.

Recently, significant developments arose when Altimmune released the results of a pivotal clinical trial on June 26, 2025. The trial—named the IMPACT Phase 2b—focused on pemvidutide, a treatment aimed at metabolic dysfunction-associated steatohepatitis (MASH). While the company described the results as “positive,” the trial’s primary efficacy endpoint regarding fibrosis showed that the improvement rates were not statistically significant when compared to the placebo. Specifically, the results reported improvement percentages of 31.8% and 34.5% for the 1.2 mg and 1.8 mg dosages of pemvidutide, respectively, versus 25.9% for the placebo group.

This revelation led to a shocking 53.18% decline in Altimmune's share price in a single day, dropping by $4.10 to close at $3.61 on June 26, which raised alarms among investors. Many are now questioning whether the company provided misleading information regarding the clinical trial results, which could have prevented losses for shareholders.

If you have invested in Altimmune and have experienced losses, Pomerantz encourages you to reach out to them. Danielle Peyton, an attorney specializing in class action cases at the firm, is open to discussing the situation with affected investors. She can be contacted at [email protected] or via phone at 646-581-9980, ext. 7980.

Pomerantz LLP, which boasts a rich history in class action lawsuits, was founded by Abraham L. Pomerantz—considered the pioneer of securities class action law. Over the course of more than 85 years, the firm has established a solid reputation for representing victims of securities fraud, breaches of fiduciary duty, and corporate misdeeds. Their experience includes recovering significant damages for class members, and they continue to advocate staunchly for investor rights.

The investigation is still in its preliminary stages, and if enough interest is generated from investors, it could pave the way for a class action lawsuit. Legal experts stress the importance of swift action, as timelines for such lawsuits can be critical. If you're a shareholder in Altimmune struggling with confusion or potential losses, keeping abreast of these developments is crucial.

This situation serves as a stark reminder of the volatility inherent in pharmaceutical investments, especially those tied to clinical trials where outcomes can dramatically shift stock values. The unfolding events surrounding Altimmune are likely to be scrutinized closely by both legal experts and investors alike, as the implications could be significant for many in the financial community.

Investors are urged to stay informed and consider their options carefully. If you find yourself impacted by this situation or have questions regarding your investment in Altimmune, do not hesitate to reach out to Pomerantz LLP for assistance. Their dedicated team is available to help navigate the complexities of securities law and to evaluate potential avenues for recourse following such damaging disclosures.